Sarepta Therapeutics (SRPT) shares rallied on Wednesday amid speculation that the company’s DMD drug eteplirsen will be approved by the FDA. The speculation was fueled by the rumor that eteplirsen reviewer Ron Farkas has left the agency. Farkas was the most direct in his opinion that the company had not submitted sufficient data to prove the efficacy of eteplirsen for the treatment of DMD. The best way to play SRPT is take some profit on the rumors. The upside could be significant if the drug is approved, however, it is advisable to take some profit now.